/ACTU
ACTU Stock - Actuate Therapeutics Inc
Healthcare|BiotechnologyNASDAQ
$6.98-0.57%
$0.04 (-0.57%) • Dec 19
75
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.40
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+200.9%upside
Target: $21.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ACTU
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$6.91 – $7.05
TARGET (TP)$21.00
STOP LOSS$6.42
RISK/REWARD1:25.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.33
52W High$11.99
52W Low$5.47
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A |
| Operating Income | $-25,160,734 | $-24,973,829 | $-20,206,807 |
| Net Income | $-27,285,328 | $-24,744,620 | $-20,159,401 |
| Net Margin | N/A | N/A | N/A |
| EPS | $-3.26 | $-1.65 | $-1.34 |
Company Overview
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
3 Bullish0 Neutral/Bearish
Price Targets
$20
Average Target
↑ 191.3% Upside
Now
$20
Low
$20
Average
$21
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 26th 2025 | B. Riley Securities | Initiation | Buy | $20 |
| April 22nd 2025 | Craig Hallum | Initiation | Buy | $21 |
| March 17th 2025 | H.C. Wainwright | Initiation | Buy | $20 |
Earnings History & Surprises
ACTUBeat Rate
20%
Last 5 quarters
Avg Surprise
-14.2%
EPS vs Estimate
Beats / Misses
1/3
1 met exactly
Latest EPS
$-0.25
Q4 2025
EPS Surprise History
Q4 23
No data
Q1 24
No data
Q3 24
No data
Q4 24
0.0%
$-0.55vs$-0.55
Q1 25
-13.8%
$-0.33vs$-0.29
Q2 25
-6.7%
$-0.32vs$-0.30
Q3 25
-57.9%
$-0.30vs$-0.19
Q4 25
+7.4%
$-0.25vs$-0.27
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 12, 2026 | $-0.27 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.27 | $-0.25 | +7.4% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-0.19 | $-0.30 | -57.9% | ✗ MISS |
Q2 2025 | May 15, 2025 | $-0.30 | $-0.32 | -6.7% | ✗ MISS |
Q1 2025 | Mar 13, 2025 | $-0.29 | $-0.33 | -13.8% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-0.55 | $-0.55 | 0.0% | = MET |
Q3 2024 | Sep 24, 2024 | — | $-4.20 | — | — |
Q1 2024 | Mar 31, 2024 | — | $-0.54 | — | — |
Q4 2023 | Dec 31, 2023 | — | $-0.50 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-0.41 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.39 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.39 | — | — |
Latest News
Actuate Therapeutics' Data From Its Phase 2 Trial Of Elraglusib In Metastatic Pancreatic Cancer Selected For Presentation At 2026 American Society Of Clinical Oncology Gastrointestinal Cancers Symposium
📈 PositiveBenzinga•Dec 18, 2025, 01:50 PM
Actuate Therapeutics Announces Publication Of New Data In Clinical Cancer Research From A Phase II Study; Reports Phase II Results Of Elraglusib With Platinum Chemotherapy Shows Median Survival Of 18.6 Months In Refractory Salivary Gland Cancer
📈 PositiveBenzinga•Dec 15, 2025, 01:49 PM
Actuate Therapeutics Q3 EPS $(0.25) Beats $(0.28) Estimate
📈 PositiveBenzinga•Nov 13, 2025, 10:44 PM
HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $20 Price Target
📈 PositiveBenzinga•Sep 23, 2025, 10:39 AM
Actuate Therapeutics Advances Elraglusib As Potential Backbone Therapy For Pancreatic Cancer With Phase 2 Data Supporting Upcoming FDA And EMA Submissions
📈 PositiveBenzinga•Sep 22, 2025, 12:47 PM
Actuate Therapeutics shares are trading lower after the company announced the pricing of a $15 million public offering of 2,142,858 shares at $7.00 per share.
📉 NegativeBenzinga•Sep 10, 2025, 01:13 PM
Actuate Therapeutics shares sink on pricing of $15M public offering of common stock
📉 NegativeSeeking Alpha•Sep 10, 2025, 12:51 PM
Actuate Therapeutics Prices $15M Public Offering Of 2,142,858 Shares At A Price Of $7.00/Share
➖ NeutralBenzinga•Sep 10, 2025, 12:39 PM
Actuate Therapeutics shares are trading lower after the company announced an underwritten public offering.
📉 NegativeBenzinga•Sep 9, 2025, 08:24 PM
Actuate Therapeutics Announces Underwritten Public Offering Of Common Stock With 30-Day Option For Additional 15% Share Purchase
➖ NeutralBenzinga•Sep 9, 2025, 08:19 PM
Actuate Therapeutics Files For Mixed Shelf Offering Of Up To $250M
➖ NeutralBenzinga•Sep 2, 2025, 08:38 PM
B. Riley Securities Initiates Coverage On Actuate Therapeutics with Buy Rating, Announces Price Target of $20
📈 PositiveBenzinga•Aug 26, 2025, 10:22 AM
HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $20 Price Target
📈 PositiveBenzinga•Aug 18, 2025, 10:31 AM
Actuate jumps as lead drug succeeds in mid-stage trial for pancreatic cancer
📈 PositiveSeeking Alpha•May 6, 2025, 12:29 PM
Frequently Asked Questions about ACTU
What is ACTU's current stock price?
Actuate Therapeutics Inc (ACTU) is currently trading at $6.98 per share. The stock has moved -0.57% today.
What is the analyst price target for ACTU?
The average analyst price target for ACTU is $21.00, based on 1 analyst.
What sector is Actuate Therapeutics Inc in?
Actuate Therapeutics Inc operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ACTU's market cap?
Actuate Therapeutics Inc has a market capitalization of $0.16 billion, making it a small-cap company.
Does ACTU pay dividends?
No, Actuate Therapeutics Inc does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALEC
Alector, Inc.
$1.40
Mkt Cap: $0.1B
APLT
Applied Therapeutics, Inc.
$0.13
Mkt Cap: $0.0B
ELTX
Elicio Therapeutics, Inc.
$7.94
Mkt Cap: $0.1B
MCRB
Seres Therapeutics, Inc.
$14.98
Mkt Cap: $0.1B
MOLN
Molecular Partners AG
$4.39
Mkt Cap: $0.2B
NKTX
Nkarta, Inc.
$1.79
Mkt Cap: $0.1B
PEPG
PepGen Inc.
$5.42
Mkt Cap: $0.4B
SPRO
Spero Therapeutics, Inc.
$2.32
Mkt Cap: $0.1B
VOR
Vor Biopharma Inc.
$12.41
Mkt Cap: $0.1B
VTGN
VistaGen Therapeutics, Inc.
$0.78
Mkt Cap: $0.0B
Explore stocks similar to ACTU for comparison